Copy
  HOT    
Launch Dynamite8 and Port-a-Patch mini

Launch of the Dynamite8 - automated dynamic clamp for the Patchliner

On October 1st 2019 we launched the Dynamite8, an add-on for the Patchliner for automated dynamic clamp recordings. The Dynamite8 system introduces simulated IK1 into hiPSC-CMs and compensates for imperfect seal resistances for stable recordings of action potentials from these cells. This could be a game changer for the use of hiPSC-CMs in safety pharmacology experiments. Read the press release here.  Read more about the system in the Product Flyer or contact the Patchliner team to find out more.

Launch of the Port-a-Patch mini

We're excited to launch the Port-a-Patch mini - Patch more, pay less!  Automated patch clamp just got even smaller, easier and more affordable. Read the Press Release here and find out more here.

Port-a-Patch mini Video

Find out how Brian is able to patch a cell in 60 seconds when he uses the Port-a-Patch mini! The Port-a-Patch mini is easy to learn and easy to use and is simply attached to the computer by a USB cable.
Watch the movie here.
  NEWS    
SfN, András Horváth, Competition Winners

Latest Publications


SyncroPatch 384PE (Predecessor model of the SyncroPatch 384i):
High-throughput phenotyping of heteromeric human ether-à-go-go-related gene potassium channel variants can discriminate pathogenic from rare benign variants.
Ng C-A. et al., (2019) Heart Rhythm (In Press) - Download here.

SyncroPatch 768PE (Predecessor model of the SyncroPatch 384/768i):
Spectrum of KV2.1 Dysfunction in KCNB1‐Associated Neurodevelopmental Disorders.
Kang S.K. et al., (2019) Annals of Neurology - Download here.


Patchliner:
GIRK channel activity of Hungarian mushrooms: From screening to biologically active metabolites.
Ványolós A. et al., (2019) Fitorterapia - Download here.


Port-a-Patch:
Modulation of the potassium channel KcsA by anionic phospholipids: Role of arginines at the non-annular lipid binding sites.
Poveda J.A. et al., (2019) BBA - Biomembranes - Download here.

CardioExcyte 96:
The N-termini of GRK2 and GRK3 simulate the stimulating effects of RKIP on β-adrenoceptors.
Maimari T. et al., (2019) Biochemical and Biophysical Research Communications (In Press) - Download here.

Port-a-Patch mini Contest Winners 2019!


Ding, ding, ding, we have a Winner! Well, we actually have 2 Winners! - Ph.D. Candidate Juan Manuel Capuccino from Rutgers New Jersey Medical School, USA (Far right) and Dr. Rajesh Kumar Sharma from the National University of Singapore (Far left). The two won Bluetooth-speakers from our Port-a-Patch mini competition which took place in March at the 63rd BPS meeting in Baltimore, USA. We would like to thank everyone that participated in the contest.
Likewise, don't miss out, stay up-to-date with our Nanion giveaways, events and publications by subscribing to our social media pages here:
LinkedIn
Twitter
Facebook

We Embrace Diversity at Nanion!


Meet András Horváth who moved from Hungary to Germany. One thing about András- his journey was full dreams that he has managed to accomplish! András embraces his journey. Read it all in our exclusive Employee- interview feature here

10th User Meeting Munich


We are looking forward to our annual user meeting starting today! We hope you're joining us at our headquarters in Munich on October 17th - 18th.

Download the final agenda here

Nanion is looking forward to SfN 2019!


Visit Elena Dragicevic, Maria Barthmes, Jim Costantin and Anatoly Shcherbatko at booth #514. Tell them your target and win one of 50 T-shirts which we are giving away!
Nanion loves neurons!

Poster 1: GABA and glutamate re-uptake transporters GAT1 and EAAT3 functionally investigated using a high throughput system
Date: Saturday, October 19th, 13:00-14:00
Poster number/board: 032.09/B2

Poster 2: Ion channels involved in pain pathways: An automated patch clamp approach
Date: Sunday, October 20th, 15:00-16:00
Poster number/board: 218.07/H13

Meet our partners at SB Drug Discovery at the next door booth #512 and visit their posters with data from the SyncroPatch 384PE.

Mark Your Calendar


19. - 23. October 2019:
Neuroscience 2019
(Chicago, USA). Meet Elena Dragicevic and Maria Barthmes.

27. - October - 01. November 2019:
Calcium Signalling Conference
(Fez, Morocco). We are proud to be sponsor of the Conference.

05. - 06. November 2019:
ELRIG Drug Discovery
(ACC, Liverpool, UK). Meet Ali Obergrussberger and InnoVitro's Matthias Gossmann.

27. - 29. November 2019:
Sydney Cardiovascular Symposium
(Sydney, Australia). We are proud to be sponsor of the Conference.

Snapshot of the Month

 
The Nanion team all dressed up and ready to head off to Oktoberfest 2019! 
  TOPIC    
GABA transporters: novel target for neurodegenerative diseases? 
GABA transporters: neurotransmitter: Sodium symporters 

The GABA transporters belong to the family of neurotransmitter:sodium symporters referred to as the solute carrier 6 (SLC6) family in humans. GATs co-transport GABA, Na+ and Cl- with the proposed stiochiometry 1 GABA: 2 Na+: 1 Cl-, resulting in a net influx of 1 positive charge per cycle. So far, 4 GATs have been identified, GAT1, GAT2, GAT3 and BGT13.

GAT1 is expressed throughout the brain in both GABAergic and non-GABAergic neurons, and is expressed in particularly high leves in the olfactory bulb, basal ganglia, cerebellum and retina. The physiological function of GAT1 is primarily to terminate synaptic transmission but also to ensure the fidelity of synaptic transmission by preventing the spread of neurotransmitter to neighbouring synapses. GABA transporters also play an important role in neurotransmitter reutilization. In certain circumstances, e.g. when the sodium gradient increases during ischemia or following seizures, GATs can act in reverse which may have a protective effect during seizures, by inhibiting electrical excitability.
GAT1 and its potential role in neurodegenerative diseases 

Alzheimer's disease is a neurodegenerative disease which affects millions of people globally. It is characterized by cognitive, memory and emotional regulation deficits due to a degenerative reduction in synaptic and neuronal density. It has been recently shown that GAT expression is altered in certain brain regions of Alzheimer's disease patients, providing a potential new therapeutic avenue for this debiliatating disease. Excessive removal of GABA from the synapse due to dysfunctional GATs has also been associated with a number of severe mental illnesses such as Parkinson's disease, schizophrenia and epileptic seizures. Given the importance of GAT1 in GABAergic transport, it's potential as a therapeutic target has been known for some time, indeed, the FDA approved drug Tiagabine, an antiepileptic, is a specific GAT1 inhibitor. This blocks extra removal of GABA from the synapse to maintain a concentration gradient and normal activity of GABA in the synaptic cleft.

GAT Recommended Assays, Cell Lines and Literature


GAT1 expressed in cell lines or hiPSC-CMs can be recorded using the SURFE2R instruments.

Recommended assays:
  • SURFE2R N1 (Electrogenic transporter recordings): EC buffer exchange)
  • SURFE2R 96SE (96 parallel electrogenic transporter recordings): EC buffer exchange)

Recommended cell lines:
  • Axaam (Human GAT1 HEK cell line)

Recommended hIPSC-CMs:

Read two brand new GAT Application Notes!

Visit our website for more Application Notes!
Website
Nanion Twitter
Nanion Facebook
Nanion YouTube Channel
Nanion Email
Share Share
Share Share
Tweet Tweet
Forward Forward
Copyright © 2019 Nanion Technologies GmbH, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list